Viewing nowCombinationGlycitamet XR Sustained Release Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Donggu Bio Pharmaceutical

MFDS item code 202201952 · Approved 2022.05.11 · Insurance code 657308720
Improvement of glycemic control in type 2 diabetes
This medication is used in conjunction with dietary therapy and exercise therapy to help blood sugar control in patients with type 2 diabetes. The combination of sitagliptin and metformin effectively improves blood sugar levels, assisting in diabetes management. This supports patients in achieving more stable blood sugar control.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg extended-release tablet or the 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of two 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin. No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication is a diabetes treatment containing both sitagliptin and metformin. First, serious allergic reactions may occur while taking this medication; if symptoms such as skin rash, hives, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a doctor. Additionally, there is a risk of pancreatitis, which is inflammation of the pancreas; if symptoms like abdominal pain, vomiting, or loss of appetite occur, notify healthcare professionals immediately. The metformin component in this medication can cause lactic acidosis, a rare but very dangerous metabolic condition, so it should not be taken when severe dehydration, heart disease, liver disease, severe infection, or acute kidney function decline is present. Particularly, if renal function is moderately or severely impaired, or if there are plans to undergo tests using iodine contrast agents, discontinuation should occur, and it should only be resumed after renal function has been confirmed to be normal. Pregnant women or women who may become pregnant and nursing mothers should not take this medication. There is a risk of hypoglycemia with this medication, so patients should be cautious about missing meals, having irregular eating habits, excessive exercise, or taking it in combination with other hypoglycemic agents. Also, patients with impaired liver or kidney function, elderly patients, and those with poor nutritional status need to be more cautious while taking this medication and should undergo regular blood tests and kidney function tests. Patients scheduled for surgery or with severe infections or trauma should temporarily discontinue this medication, resuming after their condition stabilizes. Finally, it is recommended to avoid alcohol consumption while taking this medication, and if any abnormal symptoms or discomfort are experienced during use, consult a doctor immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering. It is best to maintain a storage temperature between 1°C and 30°C room temperature. This will help maintain the efficacy and safety of the medication.
Bright blue, oval-shaped sustained-release film-coated tablet with a convex surface on both sides.
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Donggu Bio Pharmaceutical
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.